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Abstract
Background: Vitamin/mineral supplements are among the most commonly used treatments for autism, but the
research on their use for treating autism has been limited.
Method: This study is a randomized, double-blind, placebo-controlled three month vitamin/mineral treatment
study. The study involved 141 children and adults with autism, and pre and post symptoms of autism were
assessed. None of the participants had taken a vitamin/mineral supplement in the two months prior to the start of
the study. For a subset of the participants (53 children ages 5-16) pre and post measurements of nutritional and
metabolic status were also conducted.
Results: The vitamin/mineral supplement was generally well-tolerated, and individually titrated to optimum benefit.
Levels of many vitamins, minerals, and biomarkers improved/increased showing good compliance and absorption.
Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-
adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione
to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001),
NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001). Most of these metabolic biomarkers improved to normal
or near-normal levels.
The supplement group had significantly greater improvements than the placebo group on the Parental Global
Impressions-Revised (PGI-R, Average Change, p = 0.008), and on the subscores for Hyperactivity (p = 0.003),
Tantrumming (p = 0.009), Overall (p = 0.02), and Receptive Language (p = 0.03). For the other three assessment
tools the difference between treatment group and placebo group was not statistically significant.
Regression analysis revealed that the degree of improvement on the Average Change of the PGI-R was strongly
associated with several biomarkers (adj. R
2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being
the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
Conclusions: Oral vitamin/mineral supplementation is beneficial in improving the nutritional and metabolic status
of children with autism, including improvements in methylation, glutathione, oxidative stress, sulfation, ATP, NADH,
and NADPH. The supplement group had significantly greater improvements than did the placebo group on the
PGI-R Average Change. This suggests that a vitamin/mineral supplement is a reasonable adjunct therapy to
consider for most children and adults with autism.
Trial Registration: Clinical Trial Registration Number: NCT01225198
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Vitamins and minerals (elements) are, by definition,
essential for human health, primarily due to their critical
function as enzymatic cofactors for numerous reactions
in the body, such as the production of neurotransmitters
and fatty acid metabolism Historically attention has
focused on inadequate intake of vitamins and minerals
due to poor diet as a major contributing factor to many
child health problems in the US and around the world,
including anemia (low iron), hypothyroid (low iodine),
scurvy (vitamin C deficiency), and rickets (calcium and/
or vitamin D deficiency). More recently the focus has
shifted to the relationship between relative metabolic
disturbances and developmental disorders, for example
those associated with attention deficit disorder [1-5],
learning disorders [6], and intellectual development [7].
Children with autism sometimes have limited, self-
restricted diets, and in this paper we further investigate
the hypothesis that nutritional insufficiency and meta-
bolic imbalances may play a role in autism spectrum
disorders (ASD) as well.
According to a recent survey of 539 physicians, vita-
min/mineral supplements are among the most widely
recommended medical interventions for autism, and are
recommended by 49% of physicians for children with
autism [8]. However, there have been relatively few
treatment studies of vitamin/mineral supplements for
children with autism. Three studies demonstrated that
children with autism have impaired methylation
(decreased SAM), decreased glutathione, and increased
oxidative stress [9-11] compared to neurotypical chil-
dren. Two open-label studies demonstrated that nutri-
tional supplementation - with vitamin methyl-B12,
folinic acid, and (in one of the studies) trimethylglycine
- resulted in statistically significant improvements in
methylation, glutathione, and oxidative stress [9,10]. A
30-week, double-blind, placebo-controlled study [12] of
high-dose vitamin C (110 mg/ kg) found a reduction in
autism severity as measured by the Ritvo-Freeman scale.
There have been 11 double-blind, placebo-controlled
studies of very high dose vitamin B6 with magnesium,
with almost all showing positive behavioral improve-
ments. However, the studies were somewhat limited by
methodological problems including small sample size
and the use of assessment tools of limited validity [13].
There was one published study of a multi-vitamin/
mineral supplement for children with ASD [14], which
used a randomized, double-blind, placebo-controlled
design. None of the children in the study were on a vita-
min/mineral supplement for two months prior to the
study. They found that the treatment group generally
improved more than the placebo group, with statistically
significant greater improvements in sleep (p = 0.03) and
gastrointestinal problems (p = 0.03), both of which are
very common in autism [15-19].
Due to the promising results of the 2005 study of a
moderate dosage multi-vitamin/mineral supplement
[14], in 2007/2008 we conducted a small (n = 10) open-
label pilot study of a customized vitamin/mineral
supplement for children with ASD, which included
extensive pre and post measurements of nutritional sta-
tus (vitamins, minerals, amino acids) and metabolic
functioning (oxidative stress, methylation, glutathione,
sulfation, and neurotransmitters). The supplement was
well-absorbed (as indicated by increases in blood levels
and urinary excretion), and improved levels of glu-
tathione and some neurotransmitters. The results of
that pilot study were used to reformulate the supple-
ment, adjusting the level of some ingredients slightly up
or down based on the laboratory findings.
In 2008/2009 this revised “second generation” supple-
ment was used to conduct a randomized, double-blind,
placebo-controlled three-month treatment study, the
results of which are being reported in this paper. As the
p r e l i m i n a r yp h a s et ot h et r e a t m e n ts t u d y ,ad e t a i l e d
comparison study was conducted of the nutritional and
metabolic status of the children with autism (N = 55,
recruited for the treatment study) vs. neurotypical chil-
dren of similar age, gender and locale. The significant
findings of the baseline study [20] are summarized as
follows. Levels of biomarkers for the neurotypical con-
trols were in good agreement with accessed published
reference ranges, which provided validation of the over-
all measurement methodology. The average levels of
vitamins, minerals and most amino acids for the autism
group were within published reference range for nutri-
ents commonly measured in clinical care, but sometimes
in the lower or higher end of the reference range. The
autism group had many statistically significant differ-
ences (p < 0.001) in their average levels of biomarkers
compared to the neurotypical group, including: Low
levels of biotin, glutathione, S-adenosylmethionine
(SAM), plasma adenosine-5’-triphosphate (ATP),
reduced nicotinamide adenine dinucleotide (NADH),
reduced nicotinamide adenine dinucleotide phosphate
(NADPH), plasma sulfate (free and total), and plasma
tryptophan; also high levels of oxidative stress biomar-
kers and evidence of impaired methylation (high uri-
dine). A stepwise, multiple linear regression analysis
demonstrated significant associations between all three
autism severity scales and several groups of biomarkers,
including vitamins (adjusted R
2 of 0.25-0.57), minerals
(adj. R
2 of 0.22-0.38), and plasma amino acids (adj. R
2 of
0.22-0.39). Thus, it appears that many of these biomar-
kers are different in children with autism and signifi-
cantly associated with variations in autism severity.
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rationale for the present treatment study.
This paper presents the effect of the revised “second
generation” supplement on the nutritional/metabolic sta-
tus and symptoms of autism in children and adults.
Nutritional and metabolic biomarkers were measured at
the beginning and end of the study for a subset of the
participants (53 children ages 5-16 years). The nutritional
and metabolic status of those children at the start of the
study (pre-supplementation) was compared with that of
neurotypical children of similar age and gender and
reported previously, as discussed above [20]. Three mea-
sures of autism severity were measured pre and post, and
a fourth measure of change in autism symptoms was
measured at the end of the study.
Methods
The basic design of the study was a randomized, double-
blind, placebo-controlled study lasting three months. This
study was conducted with the approval of the Human
Subjects Institutional Review Board of Arizona State
University.
Participants
The participants were recruited in two groups, an Arizona
group and a National group. Both groups were treated
identically, except that the Arizona group also participated
in an extensive pre and post analysis of their nutritional
and metabolic status, whereas the National group did not
participate in any medical assessment. The Arizona group
had a more narrow age range since some biomedical mar-
kers vary with age; the National group included children
and adults, to determine if the effect of the supplement on
symptoms depended on age. Participants were recruited
from Arizona with the help of the Autism Society of
America - Greater Phoenix Chapter and the Arizona Divi-
sion of Developmental Disabilities. National participants
were recruited with the help of the Autism Research Insti-
tute and the Autism Society of America. All parents and
(where developmentally appropriate) children signed par-
ent consent/child assent forms, and all adult participants
signed for themselves (where developmentally appropriate)
and/or their parents/guardians signed for them.
Unsupplemented neurotypical children, recruited as
part of the preliminary baseline data collection [20] pro-
vided a reference range for nutritional and metabolic
status for all of the measurements.
Enrollment criteria
1) Arizona: age 5-16 years; National: age 3-60 years old;
2) Prior diagnosis of autism, PDD/NOS, or Asperger’sb y
a psychiatrist or similar professional, with written verifica-
tion (no additional assessment was done in this study)
3) No usage of a vitamin/mineral supplement in the
last 2 months
4) No changes in any medical, dietary, behavior, or
other treatment in the last two months, and a willing-
ness to avoid any changes during the study
5) No current use of any chelation treatment
Participants
Approximately 300 applications were received, and 41
applications were rejected, primarily due to current usage
of vitamin/mineral supplements or (for the Arizona
group) due to being outside the age range. For the Ari-
zona group, 74 applications were approved, and 53 parti-
cipants enrolled in the study. For the National group, 181
applications were approved, and 88 participants enrolled
in the study. The primary reasons why some families
chose not to enroll appeared to be primarily the chance
of receiving the placebo, the amount of questionnaires to
fill out, and (for the Arizona group) the blood and urine
collections.
The characteristics of the study participants are listed
in Table 1, and their symptoms and co-morbid symp-
toms are described in Table 2. In the national study,
41% of participants were from the West, 24% came
from the South, 17% from the Midwest, 17% from
Northeast and 1% from the Pacific.
Study Protocol
1) Participant parents contacted the study coordinator,
and the study was explained by telephone. Consent/
assent forms were sent to the parents for review, and
then signed copies were mailed or brought to the study
coordinator. Initial assessments of autism severity were
conducted.
2) (Arizona only) The study physician conducted a
physical exam to determine that the children were in
adequate health for participating in the study.
3) (Arizona only) Morning blood samples were col-
lected after an overnight fast (8-12 hours). Morning
urine samples were collected, and in almost all cases
these were first-morning (overnight) urines. Samples
were sent in a blinded manner to the labs for testing.
4) Assignment and blinding: The study coordinator
assigned subject code and randomized for group assign-
ment prior to baseline data gathering. All other study
personnel (nurses, physician, laboratory staff, and PI)
remained blind to group assignment; study instructions
for all subjects were identical and provided blind to
group assignment.
5) Dosing and titration: Participants in both groups
were given a liquid (supplement or placebo) to be admi-
nistered in three equally divided doses with food at
breakfast, lunch, and dinner. Dosing was calculated and
administered on a volume basis (per ml) using supplied
oral syringes. The dosage for all subjects was slowly
titrated up to their full dose (see Dosage section below)
over the first 3 weeks of the study (or longer if
necessary).
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Page 3 of 30Table 1 Characteristics of Participants
Arizona National Group
Placebo Supplement Placebo Supplements
Total
Participants
27 26 42 46
Male 22 (81%) 25 (96%) 39 (93%) 39 (85%)
Female 5 (19%) 1 (4%) 3 (7%) 7 (15%)
Age (years) 10.5 ± 3.1 9.3 ± 3.2 9.5 +/- 5.7 13.1 +/- 10.0
Diagnosis 74% Autism;
19% Aspergers; 7% PDD/NOS
96% Autism;
4% Aspergers
67% Autism
12% Asperger’s
21% PDD/NOS
85% Autism
7% Asperger’s
9% PDD/NOS
Medications 52% no medication;
8 (30%) psycho-pharmaceuticals -
primarily risperdal and clonidine;
4 (15)% CNS stimulants (primarily
Concerta);
1 (4%) anti-convulsants;
1 (4%) asthma/allergy medications;
1 (4%) GI medications;
1 (4%) Insulin medications;
2 (7%) blood pressure medications
42% no medication;
8 (32%) psycho-pharmaceuticals -
primarily risperdal and clonidine;
1 (4%) CNS stimulants (Dextrostat);
1 (4%) anti-convulsants;
3 (12%) asthma/allergy medications;
2 (8%) GI meds
64% no medications;
10 (24%) atypical anti-
psychotics (primarily
Risperdal);
2 (5%) on CNS stimulants;
3 (7%) on anti-convulsants;
4 (10%) on allergy/asthma
medications;
1 (2%) on GI medications
52% no medications;
14 (30%) atypical anti-psychotics (primarily risperdal);
3 (7%) on CNS stimulants;
7 (15%) on anti-convulsants (primarily Depakote);
6 (13%) on allergy/asthma medications;
1 (2%) on muscle relaxants;
1 (2%) on anti-coagulants
Special Diets 67% on regular diet;
3 gluten-free, casein-free diet;
2 reduced dairy;
2 low sugar
88% on regular diet;
1 gluten-free;
1 reduced gluten;
1 reduced dairy
76% on regular diet;
11% gluten-free, casein-free
diet;
1 reduced gluten and casein
diet;
2 milk-free;
1 soy-free
1 Feingold diet
67% on regular diet;
11% gluten-free, casein-free diet;
15% reduced dairy/gluten/casein;
1 dairy-free; 1 casein-free; 1 gluten-free; 1 low sugar; 1 no red/blue
dyes; 1 lactose free; 1 low soy; 1 vegetarian; 1 no eggs
Nutritional
Supplements
None 1 on fish oil; 3 on melatonin 5% on fish oil;
1 on melatonin;
1 digestive enzymes;
1 on glucosamine &
chondroitin sulfate;
1 on constipation relief
4% on fish oil;
1 on glutamine;
1 on herbal sleep extract;
1 on multi-nutrient supplement
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06) Monitoring: Following collection of baseline data,
participants were monitored throughout the study by
telephone and/or email for individualized dosing titra-
tion and for potential adverse effects. This was done by
the study nurse with supervision from the study physi-
cian both of whom were blind to group assignment.
Monitoring decisions were made based on the assump-
tion of subject being on verum. During initial dosing
individualization, monitoring was done weekly, and then
bi-weekly (or more often if needed) during the remain-
der of the study.
7) At the end of the study (3 months), final assess-
ments of autism severity were conducted.
8) (Arizona only) At the end of the study, morning
blood and urine samples were collected again.
For the neurotypical children, only steps 1-3 were fol-
lowed - they did not participate in the treatment portion
of the study.
Supplement/Placebo Formulation
Both formulations were produced by Yasoo Health and
passed USP < 51 >, the antimicrobial effectiveness test,
and the supplement was analytically tested and found to
meet label claims. Both were predominantly water-
based, flavored with a natural cherry flavor and swee-
tened with sucralose, and both contained preservatives
(potassium sorbate and sodium benzoate). The supple-
ment also contained sucrose due to the strong flavor of
the vitamins/minerals.
The placebo was 97% water and also contained a small
amount of beta-carotene for coloring, and citric acid
and a proprietary blend of natural plant-based flavors to
create a vitamin-like after-taste. The citric acid and nat-
ural plant-based flavors were not included in the supple-
ment. A small amount of xanthum gum was used to
thicken the placebo, to simulate the viscosity of the
supplement.
The placebo was packaged identically to the supple-
ment, and based on the participants’ discussions with
the nurses (who were also blinded), it did not appear
that the participants could distinguish if they had
received the placebo or the supplement, based on taste.
Supplement
The vitamin/mineral supplement formulation is given in
Table 3, for a child of 60 lb; the dosage was adjusted up or
down proportionately according to bodyweight (measured
at the start of the study), up to a maximum of 100 pounds.
As discussed earlier, it is a “second-generation” formula-
tion, based on the results of a small unpublished pilot
study. It is a comprehensive vitamin/mineral supplement,
containing most vitamins and minerals. A comparison
with the RDA/AI and Tolerable Upper Limit [21] is
shown in Table 3. Two essential minerals, iron and cop-
per, were not included because our preliminary data sug-
gested they were not needed by most children with
autism. The form of vitamin B6 used was pyridoxine,
because that form can enter the cell and be converted into
the active form, pyridoxal-5-phosphate (P5P); in contrast,
P5P cannot enter cells [22]. The amount of vitamin B6 is
moderately high compared to the RDA because in chil-
dren with autism many B6-dependent biomarkers were
known by prior research to be abnormally low, including
glutathione and neurotransmitters. Methylsulfonyl-
methane (MSM, (CH3)2SO2)w a si n c l u d e da sas o u r c eo f
sulfate, because our pilot study found children with autism
had very low levels of plasma sulfate. Lithium, a possibly
essential mineral [23] was included because an earlier
study [24] found that children with autism and their
mothers were low in lithium, and low lithium is linked to
a wide range of psychological disorders. Note that the
dosage of lithium is similar to the typical daily intake,
and less than 1% of the level when lithium is used as a
Table 2 Symptoms of Autism Participants, per the ATEC
Subscale on Health/Physical Behavior
Symptom % with moderate or severe
problem
bedwetting 20%
wets pants/diapers 18%
soils pants/diapers 21%
diarrhea 14%
constipation 24%
sleep problems 36%
eats too much/little 48%
limited diet 47%
hyperactive 40%
lethargic 9%
hits/injures self 20%
hits/injures others 18%
destructive 20%
sound sensitive 43%
anxious/fearful 30%
unhappy/crying 12%
seizures 2%
obsessive speech 27%
rigid routines 36%
shouts/screams 38%
demands sameness 34%
often agitated 31%
not sensitive to pain 30%
hooked or fixated on certain
objects
62%
repetitive movements 43%
This section was rated on a scale of 0 (none), 1 (mild), 2 (moderate), 3
(severe). Below are listed the percentages with moderate or severe problems,
as reported by parents.
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Page 5 of 30Table 3 Formulation of vitamin/mineral supplement used in present study, and comparison to Recommended Daily
Allowance (RDA) or Adequate Intake (AI) and Tolerable Upper Limit
VITAMINS Current Supplement
(for 60 lb child)
RDA/AI (4-8 yr)
(AI values indicated by asterisk)
Upper Limit for children ages 4-8 years
Vitamin A
(palmitate)
1000 IU 400 mcg (1333 IU) 900 mcg (3000 IU)
Vitamin C
(calcium ascorbate)
600 mg 25 mg 650 mg
Vitamin D3
(cholecalciferol)
300 IU 5 mcg (200 IU)* 50 mcg (2000 IU)
Vitamin E 150 IU 7 mg (10.5 IU) 300 mg (450 IU)
Mixed Tocopherols 70 mg n/a n/a
Vitamin K 0 55 mcg* ND
B1
(thiamin HCl)
20 mg 0.6 mg ND
B2
(riboflavin)
20 mg 0.6 mg ND
B3
(niacin/niacinamide)
15 mg niacin
10 mg niacinamide
8m g 1 5m g
B5 (calcium d-pantothenate) 15 mg 3 mg* ND
B6 (pyridoxine HCl) 40 mg 0.6 40 mg
B12 (cyanocobalamin) 500 mcg 1.2 mcg ND
Folic Acid 100 mcg 200 mcg 400 mcg
Folinic Acid 550 mcg
Biotin
(biotin)
150 mcg 12 mcg* ND
Choline
(choline chloride)
250 mg 250 mg* 1000 mg
Inositol 100 mg n/a n/a
Mixed Carotenoids 3.6 mg n/a n/a
Coenzyme Q10 50 mg n/a n/a
N-acetyl cysteine 50 mg n/a n/a
MINERALS
Calcium
(from calcium ascorbate)
100 mg 800 mg* 2500 mg
Chromium
(chromium amino acid chelate)
70 mcg 15 mcg* ND
Copper 0 440 mcg 3000 mcg
Iodine
(potassium iodide)
100 mcg 90 mcg 300 mcg
Iron 0 1 0m g 4 0m g
Lithium
(lithium orotate)
500 mcg n/a*** n/a
Magnesium
(magnesium chloride hexahydrate)
100 mg 130 mg 110 mg**
Manganese
(manganese amino acid chelate)
3 mg 1.5 mg* 3 mg
Molybdenum
(sodium molybdate dihydrate)
150 mcg 22 mcg 600 mcg
Phosphorus 0 500 mg 3000 mg
Potassium
(potassium chloride)
50 mg 3.8 g* n/a
Selenium
(selenomethionine and sodium selenite)
22 mcg 30 mcg 150 mcg
Adams et al. BMC Pediatrics 2011, 11:111
http://www.biomedcentral.com/1471-2431/11/111
Page 6 of 30psychiatric medication. Coenzyme Q-10 was added to
support mitochondrial function. A low dose of N-acetyl-
cysteine was included to enhance production of glu-
tathione. This formulation contained a water soluble form
of vitamin E (d-Alpha-Tocopheryl Polyethylene Glycol-
1000 Succinate) that has shown to improve the absorption
of fat-soluble vitamins in patients with malabsorption
[25-28].
Dosage
All participants (children and adults) received either the
supplement or placebo, and the dosage was adjusted
b a s e do nb a s e l i n em e a s u r e db o d yw e i g h tu pt oam a x i -
mum of 100 pounds (see Table 3). Based on prior stu-
dies dosage levels of nutrients in the supplement were
chosen to be significantly higher than RDA levels, but
either at or below the Tolerable Upper Limit. The sup-
plement/placebo was administered by the parents (or
school staff at lunchtime). Compliance was monitored
by a daily checklist, and was above 95% in all cases.
The study dose was gradually increased during the
first 3 weeks of the study:
Days 1-4: 1/6 of full dose
Days 5-8: 2/6 of full dose
Days 9-12: 3/6 of full dose
Days 13-16: 4/6 of full dose
Days 17-20: 5/6 of full dose
Days 21 and later: full dose.
The dosage was individually titrated in cases where par-
ents reported possible adverse effects (see section on
Withdrawals/Removals/Adverse Effects), with the dosage
being lowered temporarily in some cases. By the end of
the study, most participants were at the full dose, except
for 2 children on the placebo and 6 children on the sup-
plement (they ended at 50%-83% of the full dose). Thus,
for most children the full dosage was well-tolerated, but
for approximately 10% a slightly lower dosage was used to
reduce or eliminate side-effects.
Lab Measurements
Blood and urine samples were sent in a blinded fashion
to two laboratories, Vitamin Diagnostics and Doctor’s
Data, for evaluation. Details of the measurement
methods are given in another paper [20]. Both labora-
tories are certified by CLIA, the Clinical Laboratory
Improvement Amendments program operated by the
US Department of Health and Human Services which
oversees approximately 200,000 laboratories in the US,
and the tests reported in the paper are CLIA-approved
tests.
Assessing Autistic Symptoms and Severity
Three tools were used by the same parent/guardian at the
beginning and end of the study to assess the severity and
symptoms of autism, namely the Pervasive Development
Disorder Behavior Inventory (PDD-BI) [29], Autism Eva-
luation Treatment Checklist (ATEC) [30], and Severity of
Autism Scale (SAS) [31]. For the PDD-BI, we used a
slightly modified Autism Composite, in which the Seman-
tic/Pragmatic Problems (SemPP) subscale is ignored. The
reason is that the SemPP is difficult to interpret, since chil-
dren with no spoken language inappropriately score as less
severe than those with limited language. Therefore, follow-
ing the example of our previous study [31] we exclude the
SemPP subscale in calculating the Autism Composite
score, resulting in a modified Autism Composite score
consisting of Sensory/Perceptual Approach, Ritualisms/
Resistance to Change, Social Pragmatic Problems, Social
Approach Behaviors, Phonological and Semantic Prag-
matic subscales.
I na d d i t i o n ,w eu s e dar e v i s e df o r mo ft h eP a r e n tG l o -
bal Impressions (PGI-R), which we introduce here. It was
evaluated at the end of the study only, since it only
assesses changes in symptoms. The original Parent Glo-
bal Impression (PGI) [14] was a simple list of 8 symp-
toms, including Expressive Language, Receptive
Language, General Behavior, Gastrointestinal Symptoms,
Sleep, Sociability, Eye Contact, and Overall. The symp-
toms were rated on a scale of 1-7, where 1 = much
worse, 2 = worse, 3 = slightly worse, 4 = no change, 5 =
slightly better, 6 = better, 7 = much better. The PGI-
Revised replaces the “General Behavior” category in the
PGI with the more specific categories of Hyperactivity,
Tantrumming, Cognition, and Play. Also, an Average
Change score is computed, based on the average of the
individual scores. Finally, the scale is changed from a
Table 3 Formulation of vitamin/mineral supplement used in present study, and comparison to Recommended Daily
Allowance (RDA) or Adequate Intake (AI) and Tolerable Upper Limit (Continued)
Sulfur
(MSM)
500 mg n/a n/a
Zinc
(zinc gluconate)
12 mg 5 mg 12 mg
Other Ingredients in Current Supplement Natural cherry flavor; sucrose, sucralose; preservatives (potassium sorbate, sodium benzoate).
ND: none determined
* Adequate Intake
** for Magnesium, the UL is the amount for supplements and does not count food sources
*** Estimated daily intake of lithium in food is 1900 mcg/day for adults.
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Page 7 of 30range of 1-7 to a range of -3 to +3; ie, -3 = much worse,
0 = no change, and +3 = much better.
Statistical Analysis
Several types of statistical analyses were used, depending
on the research question being addressed. In comparing
levels between groups (such as children with autism vs.
neurotypical children), 2-sided unpaired t-tests were
used. The unpaired t-tests we r ee i t h e rd o n ea s s u m i n g
equal variance (if p-values for F-tests for equal variance
w e r eg r e a t e rt h a n0 . 0 5 ) ,o ra s s u m i n gu n e q u a lv a r i a n c e
(if F-test p-value results were less than 0.05). For indivi-
dual comparisons a p value of 0.05 or lower was
assumed significant. However, when multiple compari-
sons were considered, then a lower p-value was consid-
ered significant based on a Bonferroni analysis - this is
d e f i n e da tt h eb e g i n n i n go fe a c hs e c t i o no ft h er e s u l t s .
In other words, if one asks the question “did the level of
vitamin B6 improve”,ap - v a l u eo f0 . 0 5i ss u f f i c i e n tf o r
95% confidence. However, if one asks the question “did
the level of any of the vitamins improve”, then a Bonfer-
roni correction is used. This study is exploratory in that
we are investigating many hypotheses; i.e., will vitamin/
mineral supplementation affect the level of vitamins,
minerals, and metabolic fa c t o r s .T h i si sn e c e s s a r y
because the supplement contains many vitamins and
minerals, so it is expected to affect the levels of many of
those, as well as other nutritional and metabolic markers
that depend on them.
Pearson Correlation coefficients were obtained to
determine the strengths of linear relationships among
the variables involved in the analyses.
Note that for a few measurements there was some
data below our detection limit. In those cases we substi-
tuted the value of the detection limit for the data point;
so, for cases where some samples were below detection
limit, our reported averaged values are an upper bound
to the true average value.
In this paper we focus on the percentage change (pre
to post) for each biomarker for the supplement group
and for the placebo group separately. In most cases
there were few significant changes in the placebo group,
so supplement vs. placebo group comparisons were not
made. Randomization of the ASD children sometimes
resulted in somewhat different baseline values for some
analytes. Thus in data analysis a paired t-test comparing
child to self was chosen instead of unpaired t-test com-
paring the two groups.
Regression analysis was employed to examine the rela-
tionship between the Average Change of the PGI-R and
the biomarkers of nutritional and metabolic status, for
the Arizona supplement group only. For the selected
dependent and independent variables, step-wise linear
regression analyses were conducted. The initial variables
were the variables with the strongest correlation to the
PGI-R. Then at each step, the variable with the highest
p-value was eliminated, and this process was continued
until the adjusted R
2 value began declining. Thus, the
goal was to determine the best fit to the sample data for
the selected model, taking into account the correlation
among the independent variables.
Participant Withdrawals, Removals, and Adverse Effects
Figure 1 displays a flow chart of the study. Two of the chil-
dren with autism from the initial baseline evaluation [20]
did not start the supplement study. The withdrawals/
removals included:
Placebo Group (11 withdrawals, including 5 due to
adverse effects)
4 participants withdrew because their parents lost
interest in the study
1 child was removed by the PI due to a change of
school
1 participant began behavior medication 1 week into
study and was removed by the PI
3 cases of loose stools/ diarrhea (all 3 had gut issues
prior to starting, and the continuation of those
symptoms caused them to drop out)
1 participant had increased stimming (rubbing face)
- history of this, but seemed to worsen
1 participant withdrew due to behavior problems
Treatment Group (8 withdrawals, including 3 due to
adverse effects)
2 participants were removed from the study because
they made changes in their psychiatric medications
in the first few weeks of the study.
1 participant dropped due to an appendectomy dur-
ing the first week of the study.
1 participant was removed at the beginning of the
study because the study physician judged that their
initial gut problems (prior to starting the supple-
ment) required immediate treatment which required
exclusion from the study
1 participant was removed because their parent misun-
derstood the dosage and gave 10× the specified dosage
for the first two weeks. The child was receiving the
real supplement, and was doing very well with no
adverse effects. They completed a Parent Global
Impressions-Revised form and reported some of the
highest improvements of any child in the study.
1 case of aggressive behavior, night terrors, trouble
focusing - history of this, but seemed to worsen
1 case of aggressive behavior, moody - history of
this, but seemed to worsen
1 case of nausea/diarrhea at lowest dose (person had
long history of having similar reactions to almost all
vitamin supplements)
Adams et al. BMC Pediatrics 2011, 11:111
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Page 8 of 30Some mild temporary adverse effects were reported
in both the supplement and placebo group, generally
related to mild behavior problems (approximately 11%
and 7%, respectively) or diarrhea/constipation
(approximately 11% and 7%, respectively), but did not
cause participants to withdraw. Most adverse effects
were encountered during individualized titration and
resolved by slowing the rate of increase to full dose or
l o w e r i n gt h ed o s a g e( s e ed o s a g es e c t i o n )o ft h es u p p l e -
ment/placebo. These reports occurred in both the sup-
plement and placebo group, so some were probably
due to normal fluctuation in existing autistic
symptoms.
In the National group only, there were 18 participants
who completed the study but did not fill out the final
evaluation forms despite several requests (7 cases in the
placebo group, and 11 cases in the supplement group).
This did not occur in the Arizona group, because those
families filled out forms when they returned for their
final blood draws.
Combining the Arizona and National groups, 141 chil-
dren and adults started the study, 19 withdrew, 18 did
not complete final paperwork, and 104 completed the
study and filled out the final evaluations, with 51 in the
placebo group and 53 in the supplement group.
Results
Nuritional/Metabolic Results
In this section we discuss ther e s u l t sf o rt h eA r i z o n a
participants who began and ended the study, including
21 in the Treatment group and 24 in the Placebo
group. However, in a few cases blood or urine mea-
surements were not available both pre and post, due to
problems including compliance with blood and urine
collection, incomplete blood draws, and loss of samples
due to shipping or laboratory errors. The tables specify
the number of complete cases for each category of
measurements; incomplete cases (lack of data for
beginning or end of study) are not included in those
tables or in the analysis. In all tables the values for the
Neurotypical Controls (N = 44) from the preliminary
phase of the overall study are included as a contem-
poraneous reference range; the samples from the neu-
rotypical controls were obtained in the same sessions
as for the autism group, in an identical manner, and
shipped together in a blinded fashion to the labora-
tories for testing.
Vitamins
Table 4 shows the levels of vitamins and related sub-
stances, and Figure 2 shows the significant changes for the
Initial Treatment Group
(n=72)
Initial Placebo Group
(n=69)
Initial ASD Group
(Arizona and National)
n=141; randomized 
into two groups
8 withdrawals/
removals:
2 – med changes
1- appendectomy
1 – pre-existing GI 
problem 
1 – 10x dose
2- behavior 
problems
1- nausea at lowest 
dose
Finished Treatment
(n=64)
Finished Placebo
(n=58)
11 withdrawals: 
1- med change
4- family lost interest
1- changed school
1 – behavior problems
3- loose stools/diarrhea
1- increased stimming
Finished Treatment 
and completed forms
(n=53)
Finished Placebo and 
completed forms
(n=51)
7 finished study but did 
not complete final 
forms 
11 finished treatment 
but did not complete 
final forms
Figure 1 Study Flow Chart.
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Page 9 of 30Table 4 Vitamins: The average levels of vitamins measured in the Neurotypical group and the Autism Treatment and Autism Placebo groups (pre and post)
who completed the study are reported below, along with their standard deviations.
Vitamins Units Neuro-typicals
(n = 44)
Arizona Treatment Group
(N = 18)
Arizona Placebo Group
(N = 22)
Pre Post % change p-value Pre Post % change p-value
Vit. A (plasma) ug/100 ml 54.9
+/- 12
62.3
+/- 12
59.0
+/-13
-5% n.s. 50.2
+/- 7.2
52.9
+/-13
+5% n.s.
Total Carotenes
(beta carotene and other carotenes, in plasma)
ug/
100 ml
178
+/-53
158
+/- 53
170
+/- 65
+7% n.s. 136
+/- 53
150
+/-59
+10% n.s.
Vit B1
Thiamine
(WB)
ug/l 63
+/-9
63
+/- 12
80
+/-12
+27% 0.0005 65
+/-9
65
+/-11
0% n.s.
Vit B2
Riboflavin
(WB)
ug/l 282
+/-52
291
+/- 42
295
+/-36
1% n.s. 272
+/- 45
262
+/-55
-3% n.s.
Vit B3
Niacin and Niacinamide
(WB)
ug/l 7.07
+/-1.0
6.7
+/- 1.1
7.3
+/-0.9
+9% 0.04 7.1
+/- 1.3
7.2
+/-1.0
+1% n.s.
Vit B5
Pantothenic Acid
(WB)
ug/l 714
+/-180
654
+/- 104
748
+/-170
+14% 0.06 600
+/- 117
629
+/-159
+5% n.s.
Vit B6 (as P5P in RBC) ug/l 15.2
+/-5.3
20.3
+/- 15
58.1
+/-24
+187% 0.00001 17.8
+/- 14
16.1
+/-11
-10% n.s.
Folic Acid (serum) ug/l 18.7
+/-6.1
20.1
+/- 7.5
26.3
+/-7.1
+31% 0.03 15.3
+/- 4.8
17.8
+/-8.2
17% 0.09
Vit B12
(plasma)
ng/l 676
+/-215
696
+/- 231
835
+/-259
+20% 0.002 690
+/- 240
639
+/-246
-7% n.s.
Vit C
(plasma)
mg/
100 ml
1.33
+/-0.46
1.59
+/- 0.60
2.08
+/-0.34
+31% 0.007 1.60
+/- 0.59
1.55
+/-0.51
-3% n.s.
Vit D3
(25-hydroxy in plasma)
ug/l 28.6+/-8.5 29.6
+/- 8.3
25.4
+/-6.2
-14% 0.04 28.9
+/- 8.7
25.9
+/-7.8
-10% n.s.
Total Vit E (serum) mg/
100 ml
0.90
+/-0.32
0.78
+/- 0.16
0.97
+/-0.21
+24% 0.002 0.75
+/- 0.19
0.84
+/-0.24
+12% n.s.
Biotin (WB) ng/l 491
+/-164
395
+/- 115
595
+/-225
+51% 0.008 377
+/- 88
527
+/-162
+40% 0.001
Vit K (plasma) nmol/l 295
+/- 189
288
+/- 116
330
+/- 165
+15% n.s. 317
+/- 197
277
+/- 98
-13% n.s.
Vitamin-like substances
Free Choline
(RBC)
mg/l 5.6
+/- 1.7
6.7
+/- 3.5
5.9
+/- 2.0
-12% n.s. 6.4
+/- 2.3
7.0
+/- 1.7
+10% n.s.
Total Choline
(RBC)
mg/l 310
+/- 51.4
363
+/- 59
343
+/- 43
-5% n.s. 361
+/- 67
368
+/- 42
+2% n.s.
Lipoic Acid
(plasma)
ug/l 2.9
+/- 1.2
3.1
+/- 1.8
2.3
+/- 0.7
-22% n.s. 2.3
+/- 1.5
2.1
+/- 1.2
-9% n.s.
A
d
a
m
s
e
t
a
l
.
B
M
C
P
e
d
i
a
t
r
i
c
s
2
0
1
1
,
1
1
:
1
1
1
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
3
1
/
1
1
/
1
1
1
P
a
g
e
1
0
o
f
3
0Table 4 Vitamins: The average levels of vitamins measured in the Neurotypical group and the Autism Treatment and Autism Placebo groups (pre and post)
who completed the study are reported below, along with their standard deviations. (Continued)
Biomarkers of functional need for vitamins
FIGLU ug/l 1.62
+/- 0.72
1.87
+/- 0.93
1.32
+/- 0.64
-29% 0.01 2.11
+/- 0.91
1.85
+/- 0.98
-12% n.s.
Methylmalonic Acid mg/g-creat 7.2
+/- 4.8
8.2
+/- 5.6
4.8
+/- 4.2
-41% 0.03 6.7
+/- 5.7
8.7
+/- 10.4
+30% n.s.
N-methyl-nicotinamide mg/g-creat 3.44
+/- 2.1
4.62
+/- 3.5
3.1
+/- 1.6
-33% n.s. 4.94
+/- 5.1
5.15
+/- 3.1
+4% n.s.
Kryptopyrroles ug/dl 35.8
+/- 15
38.0
+/- 23
36.2
+/- 29
-5% n.s. 40.3
+/- 29
38.1
+/- 24
-5% n.s.
The p-value for a t-test comparison of the change in the level is reported. If the p-value is below 0.05 then the result is highlighted.
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0treatment group. There are a total of 21 comparisons, so
in this section statistically “significant” is defined as p <
0.002, “marginally significant” as p < 0.005, and “possibly
significant” as p < 0.05.
Treatment Group
After supplementation for 3 months, the supplement
group had significant increases (p < 0.002) in vitamins B1,
B6, B12, and E. There were possibly significant (p < 0.05)
increases in vitamin B3, C, biotin, and folic acid, and a
possible decrease in vitamin D (due to seasonal effects
-see discussion section). There were also possibly signifi-
cant decreases in FIGLU and methylmalonic acid, indicat-
ing that the need for folic acid and vitamin B12,
respectively, had been met.
Placebo Group
There was a very significant increase in biotin (p <
0.001), but no other significant or possibly significant
changes in vitamins. The increase in biotin may be due
to fluctuations in diet, seasonal changes, or the plant-
based extract which was used in the placebo (not the
supplement) to give it a “vitamin-like” flavor.
Essential Minerals
Table 5 shows the levels of minerals in whole blood
(WB), RBC, serum, and urine (for iodine) for the study
participants. There are a total of 30 comparisons, so in
this section statistically “significant” is defined as p <
0.0017, “marginally significant” as p < 0.0034, and “pos-
sibly significant” as p < 0.05.
Treatment Group
Overall, there were many significant and possibly signifi-
cant improvements in essential minerals - see Table 5
and Figure 3. The major improvements were significant
large increases in WB lithium, WB manganese, and RBC
calcium. There was a large and possibly significant
increase in urinary iodine and WB molybdenum. There
was a possibly significant decrease (improvement) in
RBC iron, from a level above the average of the neuroty-
picals to a level slightly lower than the neurotypical aver-
age. There was a similar, but non-significant, decrease in
serum ferritin. In all, supplementation tended to normal-
ize the minerals, i.e. increasing if low and decreasing if
high in comparison to control reference range.
There were also some minor changes. There was a
small, statistically significant increase in WB magnesium
but a small decrease in RBC magnesium that was possibly
significant. Similarly there was a small, statistically signif-
icant increase in WB selenium, but a possibly significant
decrease in RBC selenium (note that the concentration of
selenium in WB is vastly greater than the concentration
60%
70%
80%
90%
100%
110%
120%
130%
140%
150%
160%
B1 B3 B6 Folic
Acid
B12 Vit C Vit D3 Vit E Biotin FIGLU MMA
Control Pre-Treatment Post-Treatment
Figure 2 Level of vitamins and related substances in neurotypical controls and in the Arizona autism treatment group (pre and post),
normalized to the level in the control group. The average values are shown. The number of asterisks indicates the p-value for the t-test of
the change in the biomarker from pre-treatment to post-treatment in the autism group (* p < 0.05, ** p < 0.01, *** p < 0.001). Note that the
post-treatment value for Vitamin B6 is off the scale.
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Page 12 of 30Table 5 Minerals: The average levels of minerals measured in the Neurotypical group and the Arizona Autism Treatment and Arizona Autism Placebo groups
(pre and post) who completed the study are reported below, along with their standard deviations
Essential Minerals + other minerals Neuro-typicals
(n = 44)
Treatment Group
(n = 19)
Placebo Group
(n = 20)
Pre Post % change p-value Pre Post % change p-value
Calcium-WB
(mg/dL)
5.8
+/- 0.3
5.9
+/- 0.4
6.0
+/0.4
+1% n.s. 5.8
+/- 0.3
5.6
+/- 0.5
-2% n.s.
Calcium-RBC
(ug/g)
22.4
+/- 6
19.2
+/- 7.9
27.4
+/- 3.6
+43% 0.001 19.5
+/- 7.5
25.2
+/- 4.3
+30% 0.02
Calcium-Serum
(mg/dL)
9.60
+/- 0.2
9.65
+/- 0.4
9.51
+/- 0.3
-1% 0.07 9.59
+/- 0.4
9.53
+/- 0.3
0% n.s.
Chromium-RBC
(ng/g)
0.80
+/- 0.4
1.02
+/- 0.50
0.81
+/- 0.6
-21% n.s. 0.77
+/- 0.44
0.70
+/- 0.3
-9% n.s.
Copper-WB
(ug/dL)
89
+/- 14
91.2
+/- 13
95.9
+/- 17
+5% 0.09 93.9
+/- 10
95.5
+/- 13
+2% n.s.
Copper-RBC
(ug/g)
0.72
+/- 0.09
0.75
+/- 0.08
0.78
+/- 0.08
+4% 0.06 0.74
+/- 0.08
0.77
+/- 0.08
+4% n.s.
Iodine-Urine
(ug/mg creatinine)
0.26
+/- 0.2
0.28
+/- 0.26
0.43
+/- 0.27
+54% 0.03* 0.23
+/- 0.15
0.22
+/- 0.15
-5% n.s.
Iron-RBC
(ug/g)
833
+/- 64
887
+/- 101
806
+/- 54
-9% 0.006 883
+/- 80
826
+/- 51
-7% 0.02
Iron-Serum
(ug/dL)
87
+/- 35
91
+/- 34
88
+/- 46
-3% n.s. 80
+/- 33
81
+/- 25
+2% n.s.
Serum Ferritin 36.9
+/- 17
42.1
+/- 23
37.3
+/- 23
-11% n.s. 41.3
+/- 25.1
33.4
+/- 22
-19% 0.004
Lithium-WB
(ug/L)
3.6
+/- 6
1.82
+/- 0.8
10.6
+/-5.1
+485% .000001 1.60
+/- 0.7
1.47
+/- 0.7
-8% n.s.
Magnesium-WB
(mg/dL)
3.64
+/- 0.26
3.44
+/- 0.19
3.62
+/- 0.25
+5% 0.00007 3.65
+/- 0.41
3.81
+/-0.42
+4% 0.03
Magnesium-RBC (ug/g) 47.5
+/- 5
48.6
+/- 7.5
44.9
+/- 4.0
-8% 0.03 49.4
+/- 5.8
47.9
+/- 6.0
-3% n.s.
Magnesium-Serum
(mg/dL)
2.03
+/- 0.15
1.90
+/- 0.13
1.95
+/- 0.15
+2% n.s. 1.93
+/- 0.14
1.97
+/- 0.15
+2% n.s.
Manganese-WB
(ug/L)
11.6
+/- 3
11.0
+/- 3.3
13.6
+/- 4.4
+23% 0.0006 12.0
+/- 4.7
14.5
+/- 5.0
+21% 0.00002
Manganese-RBC (ug/g) 0.018
+/- 0.005
0.019
+/- 0.007
0.019
+/- 0.006
+1% n.s. 0.020
+/- 0.006
0.019
+/- 0.007
-4% n.s.
Molybdenum-WB (ug/L) 1.39
+/- 0.3
1.27
+/- 0.23
1.88
+/- 0.9
+48% 0.007* 1.34
+/- 0.3
1.37
+/- 0.3
+3% n.s.
Molybdenum-RBC (ng/g) 0.98 +/- 0.2 1.01
+/- 0.3
1.32
+/- 0.0007
+31% 0.06* 0.87
+/- 0.26
0.93
+/- 0.2
+7% n.s.
Phosphorus-RBC (ug/g) 567
+/- 43
587
+/- 73
546
+/- 39
-7% 0.01 598
+/- 48
564
+/-37
-6% 0.002
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0Table 5 Minerals: The average levels of minerals measured in the Neurotypical group and the Arizona Autism Treatment and Arizona Autism Placebo groups
(pre and post) who completed the study are reported below, along with their standard deviations (Continued)
Phosphorus-Serum
(mg/dL)
4.58
+/- 0.5
4.52
+/- 0.5
4.47
+/- 0.6
-1% n.s. 4.57
+/- 0.5
4.68
+/- 0.7
+2% n.s.
Potassium -RBC-mEq/L 76.9
+/- 4.1
78.1
+/- 6.2
75.5
+/- 4.4
-3% n.s. 81.1
+/- 5.1
77.2
+/- 5.1
-5% 0.01
Potassium-Serum
mEq/L
4.17
+/- 0.3
4.12
+/- 0.3
4.21
+/- 0.3
+2% n.s. 4.01
+/- 0.3
4.04
+/- 0.3
1% n.s.
Selenium-WB
(ug/L)
210
+/- 20
209
+/- 25
223
+/- 28
+7% 0.001 211
+/- 39
218
+/- 44
+3% 0.05
Selenium-RBC
(ug/g)
0.23
+/- 0.03
0.251
+/- 0.025
0.235
+/- 0.03
-6% 0.007 0.244
+/- 0.052
0.221
+/- 0.04
-10% 0.002
Sodium-Serum
mEq/L
137
+/- 1
137
+/- 2
137
+/- 1
0% n.s. 138
+/- 3
138
+/- 2
0% n.s.
Vanadium-RBC
(ng/g)
0. 22 +/- 0.07 0. 22
+/- 0.09
0. 21
+/- 0.05
-5% n.s. 0.21
+/- 0.04
0.23
+/- 0.09
+10% n.s.
Zinc-WB
(ug/dL)
555
+/- 74
546
+/- 70
556
+/- 68
+2% n.s. 559
+/- 59
567
+/-59
+1% n.s.
Zinc-RBC
(ug/g)
8.9
+/- 1.4
9.1
+/- 1.5
8.6
+/- 1.2
-5% n.s. 9.1
+/- 1.1
8.8 +/- 1.2 -3% n.s.
Non-essential minerals
Boron-RBC
(ug/g)
0.025
+/- 0.007
0.031
+/- 0.015
0.022
+/- 0.008
-30% 0.004 0.025
+/- 0.013
0.019 +/- 0.010 -24% n.s.
Strontium-WB
(ug/L)
24
+/- 6
21.6
+/- 3.7
22.8
+/-4.5
+6% n.s. 29.1
+/- 10
28.6
+/-10
-2% n.s.
Biomarker data was obtained only for the Arizona autism group. The p-value for a t-test comparison of the change in the level is reported. If the p-value is below 0.05, then the result is highlighted.
* The ttest for urinary iodine and WB & RBC Molybdenum was done after a square root transformation of the data, since the initial data was not close to a Gaussian distribution.
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0in RBC). There was a possibly significant small decrease
in RBC phosphorus, from slightly high to slightly low,
but no change in serum phosphorus. There was also a
marginally significant decrease in boron, a non-essential
mineral.
Placebo Group
Overall, it appears there wasas i g n i f i c a n ti n c r e a s ei n
WB manganese, and mostly small fluctuations around
average levels in the other minerals. There was a small
marginally significant decrease in RBC selenium, and a
possibly significant very small increase in WB sele-
nium. There was a marginally significant small
decrease in RBC phosphorus, from slightly high to
slightly low. There were possibly significant increases
in RBC calcium (from slightly low to slightly high) and
WB magnesium (from average to slightly high), and
possibly significant decreases in RBC potassium (from
slightly high to average) and RBC iron (high to
average).
Sulfation, Methylation, Glutathione and Oxidative Stress
Table 6 shows the results for biomarkers of sulfation
(free and total sulfate), methylation (SAM and uridine),
glutathione (GSH), and oxidative stress (ratio of GSH:
GSSG and nitrotyrosine). There are a total of 11 com-
parisons, so in this section statistically “significant” is
defined as p < 0.005, “marginally significant” as p <
0.009, and “possibly significant” as p < 0.05.
Treatment Group
After treatment, there was a significant increase in total
sulfate, and a large and marginally significant increase in
free sulfate. The level of SAM increased significantly, and
there was a marginally significant decrease (improve-
ment) in uridine, a marker of impaired methylation.
Reduced glutathione improved significantly and nearly
normalized. Two markers of oxidative stress, levels of
nitrotyrosine and the ratio of oxidized:reduced glu-
tathione significantly improved to near-normal levels.
The level of oxidized glutathione improved to a near-nor-
mal level (possibly significant).
Figure 4 provides a comparison of the biomarkers that
changed significantly from the beginning to the end of
the study, normalized to the average level of the neuro-
typical group. In all cases there were improvements to
normal or near-normal levels, which is one of the most
significant findings of this study.
40%
60%
80%
100%
120%
140%
160%
180%
200%
Ca-RBC
I-Urine
Fe-RBC
Li-WB
Mg-WB
Mg-RBC
Mn-WB
Mo-WB
P-RBC
Se-WB
Se-RBC
Neurotypical Pre Post
***
***
***
***
*** ** **
**
**
*
*
Figure 3 Level of essential minerals in neurotypical group and in the Arizona autism treatment group (pre and post), normalized to
the neurotypical group. The average values are shown. The number of asterisks indicates the p-value for the t-test of the change in the
biomarker from pre-treatment to post-treatment in the autism group (* p < 0.05, ** p < 0.01, *** p < 0.001). Note that the post-treatment value
for lithium is off the chart. The figures uses standard abbreviations for the minerals, namely: Ca-calcium; I- iodine; Fe-iron; Li - lithium; Mg -
magnesium; Mn - manganese; Mo - molybdenum; P-phosphorus; Se - Selenium.
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Page 15 of 30Table 6 Sulfation, Methylation, Glutathione, and Oxidative Stress: The average levels measured in the Neurotypical group and the Autism Treatment and
Autism Placebo groups (pre and post) who completed the study are reported below, along with their standard deviations
Neuro-typicals
(n = 44)
Arizona Treatment Group
(n = 18)
Arizona Placebo Group
(n = 22)
Pre Post % change p-value Pre Post % change p-value
Free Sulfate
(plasma)
umol/
g-protein
4.09
+/- 2.3
1.60
+/- 0.6
2.93
+/- 2.0
+83% 0.008 1.30
+/- 0.4
1.98
+/- 1.8
+52% 0.08
Total Sulfate
(plasma)
umol/
g-protein
1566
+/- 384
1150
+/- 254
1346
+/- 236
+17% 0.001 1093
+/- 184
1163
+/- 194
+6% 0.06
SAM
(RBC)
umol/dl 228.4
+/- 12
218
+/- 17
230
+/- 16
+6% 0.003 213
+/- 12
218
+/- 13
+3% 0.005
SAH
(RBC)
umol/dl 42.6
+/- 4.4
40.7
+/- 7.4
41.4
+/- 5.0
+2% n.s. 48.5
+/- 6.9
45.4
+/- 7.1
-6% 0.03
Uridine
(plasma)
10
-6 M 7.9
+/- 2.7
16.2
+/- 9.5
10.4
+/- 4.7
-36% 0.008 16.4
+/- 6.9
14.5
+/- 5.8
-11% 0.06
Adenosine
(plasma)
10
-8 M 20.6
+/- 3.4
21.2
+/- 5.3
21.0
+/- 3.2
-1% n.s. 24.5
+/- 6.2
22.8
+/- 4.2
-7% 0.05
Inosine
(plasma)
10
-6 M 3.83
+/- 0.9
3.49
+/- 1.0
3.83
+/- 0.6
+10% 0.07 3.55
+/- 0.9
3.49
+/- 1.0
-2% n.s.
Reduced plasma glutathione (GSH) nmol/ml 4.09
+/- 0.79
3.27
+/- 0.59
3.84
+/- 0.61
+17% 0.0008 3.25
+/- 0.38
3.40
+/- 0.42
+5% n.s.
Oxidized glutathione (GSSG) nmol/ml 0.362
+/- 0.10
0.467
+/- 0.12
0.403
+/- 0.09
-14% 0.02 0.465
+/- 0.14
0.431
+/- 0.11
-7% n.s.
Ratio of oxidized to reduced plasma glutathione 0.093
+/- 0.04
0.150
+/- 0.05
0.109
+/- 0.03
-27% 0.002 0.147
+/- 0.05
0.132
+/- 0.05
-10% n.s.
Plasma nitro-tyrosine ug/l 7.4
+/- 5.1
14.1
+/- 6.5
9.9
+/- 5.4
-29% 0.004 19.0
+/0 8.6
16.3
+/- 9.2
-14% 0.10
The p-value for a t-test comparison of the change in the level is reported. If the p-value is below 0.05, then the result is highlighted. Sulfation is assessed by free and total sulfate, methylation is assessed by SAM
and uridine, glutathione is assessed by GSH, and oxidative stress is assessed by GSH:GSSG ratio and nitrotyrosine.
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There was a significant small increase in SAM, and a pos-
sibly significant small decrease in SAH and adenosine.
ATP, NADH, NADPH, CoQ10
Table 7 shows the results for ATP, NADP, NADPH, and
CoQ10. There are a total of 4 comparisons, so so in this
section statistically “significant” is defined as p < 0.01,
“marginally significant” as p < 0.025, and “possibly sig-
nificant” as p < 0.05.
Treatment Group
After supplementation, there was a large and very signif-
icant increase in the level of CoQ10, and the levels of
ATP, NADH, and NADPH all increased very signifi-
cantly to normal levels.
Figure 5 provides a comparison of the biomarkers that
changed significantly from the beginning to the end of
the study, normalized to the average level of the neuro-
typical group. ATP, NADH, and NADPH improved to
normal levels, which is one of the most significant find-
ings of this study.
Placebo Group
The level of CoQ10 increased slightly, and the increase
was significant. The levels of ATP, NADH, and NADPH
slightly improved, but the improvements were not
significant.
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Figure 4 Level of biomarkers in controls and in the Arizona autism treatment group (pre and post), normalized to the level in the
neurotypical controls. The average values and the standard deviations are shown. The number of asterisks indicates the p-value for the t-test
of the change in the biomarker from pre-treatment to post-treatment in the autism group (* p < 0.05, ** p < 0.01, *** p < 0.001).
Table 7 ATP/NADH/NADPH/Co-Q10.
Units Neuro-typicals
(n = 44)
Arizona Treatment Group
(n = 18)
Arizona Placebo Group
(n = 22)
Pre Post % change p-value Pre Post % change p-value
ATP
(plasma)
nmol/l 18.5
+/- 4.7
15.5
+/- 3.7
19.3
+/- 2.3
+25% 0.00001 14.0
+/- 4.9
15.6
+/- 3.7
+11% 0.08
NADH
(RBC)
nmol/ml 20.7
+/- 4.3
15.7
+/- 4.5
20.1
+/- 5.1
+28% .00002 15.3
+/- 3.9
16.4
+/- 4.1
+8% 0.06
NADPH
(RBC)
nmol/ml 30.9
+/- 8.5
23.0
+/- 7.7
29.9
+/- 7.1
+30% 0.001 21.9
+/- 5.3
23.9
+/- 7.2
+9% n.s.
CoQ10
(plasma)
ug/ml 0.60
+/- 0.16
0.56
+/- 0.14
1.41
+/- 0.58
+153% 0.00001 0.57
+/- 0.18
0.71
+/- 0.26
+26% 0.01
The average levels of biomarkers measured in the Neurotypical group and the Autism Treatment and Autism Placebo groups (pre and post) who completed the
study are reported below, along with their standard deviations. The p-value for a t-test comparison of the change in the level is reported. If the p-value is below
0.05, then the result is highlighted.
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Page 17 of 30Primary Plasma Amino Acids
The levels of the primary (proteinogenic) plasma amino
acids are given in Table 8. There are a total of 20 com-
parisons, so in this section statistically “significant” is
defined as p < 0.0025, “marginally significant” as p <
0.005, and “possibly significant” as p < 0.05.
Treatment Group
After supplementation, there were no significant or mar-
ginally significant changes. There were possibly signifi-
cant increases in arginine and glycine, with both
changing from slightly below the average neurotypical
value to slightly above. There was a possibly significant
decrease in serine, changing from slightly above the aver-
age neurotypical value to slightly below. In summary, all
changes involved fluctuations about the normal value.
Placebo Group
There were no significant or marginally significant
changes. There were possibly significant increases in
arginine, isoleucine, and tryptophan, and a possibly sig-
nificant decrease in serine.
Secondary Plasma Amino Acids
The levels of secondary (non-proteinogenic) plasma
amino acids are given in Table 9. Cystathione was also
measured, but all the measurements except one were
below the detectable limit of 0.05 umoles/100 ml, so
those values are not listed. There are a total of 21 com-
parisons, so in this section statistically “significant” is
defined as p < 0.0024, “marginally significant” as p <
0.0048, and “possibly significant” as p < 0.05.
Treatment Group
There were no significant or marginally significant
changes. There were possibly significant increases in
ornithine and sarcosine, and possibly significant
decreases in hydroxyproline, urea, and “homocystine +
homocysteine” (note that due to measurement methods
this is a total of homocystine and homocysteine).
Placebo Group
There were no significant or marginally significant
changes. There was a possibly significant increase in sar-
cosine and taurine, and a possibly significant decrease in
1-methyl-histidine, hydroxy proline, methionine sulfox-
ide, and phosphoserine.
Behavioral Results
Effect of Supplement on Symptoms
One of the original hypothesis is “Will the treatment
group improve more than the placebo group on one or
0
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Figure 5 Level of biomarkers in controls and in the Arizona autism treatment group (pre and post), normalized to the level in the
neurotypical controls. The average values and the standard deviations are shown. The number of asterisks indicates the p-value for the t-test
of the change in the biomarker from pre-treatment to post-treatment in the autism group (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Page 18 of 30more of the measures of autism severity?” The results
for the assessment tools are shown in Table 10. For the
PGI-R Average Change, the supplement group had a
significantly greater improvement than the placebo
group (0.67 +/- 0.65 vs. 0.34 +/- 0.54, p = 0.003). The
other three assessments had slightly greater improve-
ments in the supplement group than in the placebo
group, but none of the differences were statistically
significant. (Since the analysis included four compari-
sons, we define significant as p = 0.05/4 = 0.01).
Because the results for the PGI-R were significant, the
detailed results of the PGI-R are displayed in Figure 6
and Table 11. There are a total of 11 comparisons, so in
this section we will define “significant” as p < 0.005,
“marginally significant” as p < 0.01, and “possibly signifi-
cant” as p < 0.05. Overall, the supplement group had a
Table 8 Primary Amino Acids.
Amino Acids Neuro-typicals
(n = 44)
Arizona Treatment Group
(n = 18)
Arizona Placebo Group
(n = 20)
Pre Post % change p-value Pre Post % change p-value
Histidine 8.2
+/- 1.3
8.7
+/- 2.5
9.6
+/- 1.3
+10% n.s. 8.8
+/0 1.5
8.0
+/- 1.9
-9% n.s.
Isoleucine 5.8
+/- 1.6
5.3
+/- 1.3
5.7
+/- 1.3
+8% n.s. 5.2
+/- 0.8
6.0
+/- 1.5
16% 0.03
Leucine 10.7
+/- 2.1
11.0
+/- 2.5
11.4
+/- 2.8
+4% n.s. 10.5
+/- 2.0
10.4
+/- 1.8
-1% n.s.
Lysine 14.5
+/- 4.8
12.6
+/- 3.8
14.8
+/- 4.1
+17% 0.10 14.2
+/- 3.5
14.9
+/- 2.8
+5% n.s.
Methionine 1.75
+/- 0.34
1.84
+/- 0.57
2.02
+/- 0.48
+10% n.s. 1.92
+/- 0.45
1.93
+/- 0.64
+1% n.s.
Phenylalanine 4.83
+/- 0.83
4.61
+/- 0.55
4.68
+/- 1.0
+2% n.s. 4.36
+/- 0.63
4.65
+/- 0.66
+7% n.s.
Threonine 8.88
+/- 2.1
9.2
+/- 2.6
7.9
+/- 1.8
-14% 0.07 9.4
+/- 3.6
8.7
+/- 2.4
-7% n.s.
Tryptophan 4.33
+/- 1.0
3.32
+/- 0.9
4.11
+/- 1.7
+24% 0.06 3.47
+/- 1.1
4.17
+/- 1.3
+20% 0.04
Valine 20.5
+/- 4.3
20.6
+/- 4.3
20.0
+/- 4.2
-3% n.s. 18.4
+/- 3.5
20.2
+/- 3.7
+10% 0.06
Alanine 33.4
+/- 8.9
36.6
+/- 9.0
37.4
+/- 12
+2% n.s. 36.1
+/- 10
36.8
+/- 11
+2% n.s.
Arginine 6.7
+/- 1.8
5.9
+/- 2.2
7.5
+/- 1.6
+26% 0.006 6.9
+/- 2.0
7.8
+/- 1.5
+14% 0.02
Asparagine 4.38
+/- 0.83
4.50
+/- 1.0
4.15
+/- 1.0
-8% n.s. 4.26
+/- 1.42
3.92
+/- 0.84
-8% n.s.
Aspartate 0.82
+/- 0.39
0.83
+/- 0.37
0.88
+/- 0.33
+6% n.s. 0.69
+/- 0.21
0.82
+/- 0.37
+18% n.s.
Cystine + cysteine 3.48
+/- 0.74
3.57
+/- 0.72
3.36
+/- 1.2
-6% n.s. 3.01
+/- 0.81
3.40
+/- 0.87
+13% n.s.
Glutamate 5.83
+/- 1.8
6.9
+/- 1.5
7.66
+/- 1.5
+12% n.s. 6.4
+/- 1.5
6.6
+/- 1.5
+4% n.s.
Glutamine 41.3
+/- 6.8
43.1
+/- 8.3
38.2
+/- 5.9
-11% .08 42.4
+/- 11
38.4
+/- 5.0
-10% 0.10
Glycine 27.3
+/- 10
23.8
+/- 6.5
28.6
+/- 6.7
+20% 0.02 28.9
+/- 11
29.3
+/- 9.1
+1% n.s.
Proline 15.8
+/- 4.9
15.9
+/- 4.2
16.0
+/- 4.9
+1% n.s. 15.3
+/- 6.6
16.6
+/- 5.7
+8% n.s.
Serine 9.5
+/- 2.1
9.9
+/- 2.1
8.9
+/- 1.5
-10% 0.01 10.6
+/- 2.1
9.7
+/- 1.8
-8% 0.01
Tyrosine 6.1
+/- 1.6
5.5
+/- 1.3
5.9
+/- 1.3
+6% n.s. 5.6
+/- 1.1
6.0
+/- 1.3
+8% n.s.
The average levels of primary amino acids in plasma (in units of micromoles per 100 ml) measured in the Neurotypical group and the Autism Treatment and
Autism Placebo groups (pre and post) who completed the study are reported below, along with their standard deviations. The p-value for a t-test comparison of
the change in the level is reported. If the p-value is below 0.05, then the result is highlighted.
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Page 19 of 30Table 9 Secondary Amino Acids.
Amino Acids Neuro-
typicals
(n = 44)
Arizona Treatment Group
(n = 18)
Arizona Placebo Group
(n = 20)
Pre Post %
change
p-
value
Pre Post %
change
p-
value
1-Methyl histidine 0.355
+/- 0.12
0.354
+/- 0.15
0.369
+/- 0.10
+4% n.s. 0.407
+/- 0.14
0.329
+/- 0.094
-19% 0.05
3-Methyl histidine 0.68
+/- 0.52
0.68
+/- 0.55
0.54
+/- 0.46
-21% n.s. 0.83
+/- 0.88
0.470
+/- 0.35
-43% 0.10
Alpha-amino adipate
(31%/27% below dl)
0.088
+/- 0.044
0.084
+/- 0.035
0.099
+/- 0.052
+17% n.s. 0.079
+/-
0.031
0.095
+/- 0.053
+20% n.s.
Alpha-amino-N-butyrate 1.82
+/- 0.72
1.81
+/- 0.60
1.55
+/- 0.52
-15% n.s. 1.68
+/- 0.58
1.60
+/- 0.50
-5% n.s.
Anserine
(84%/95% below dl)
0.051
+/- 0.005
0.055
+/- 0.019
0.0054
+/- 0.016
-1% n.s. 0.052
+/-
0.0078
All results below detectable
limit
-3% n.s.
Beta-alanine 0.62
+/- 0.31
0.57
+/- 0.23
0.60
+/- 0.18
+6% n.s. 0.72
+/- 0.35
0.58
+/- 0.16
-20% n.s.
Beta-amino isobutyrate 0.138
+/- 0.088
0.170
+/- 0.070
0.162
+/- 0.077
-5% n.s. 0.172
+/-
0.077
0.170
+/- 0.072
-1% n.s.
Carnosine
(73%/84% below dl)
0.054
+/- 0.015
0.063
+/- 0.042
(All results below
dl)
-21% n.s. 0.056
+/-
0.020
0.050
+/- 0.001
-11% n.s.
Citrulline 3.02
+/- 0.52
3.02
+/- 0.69
3.34
+/- 0.98
+10% n.s. 3.02
+/- 1.0
3.15
+/- 0.80
+4% n.s.
Ethanol amine 0.94
+/- 0.63
1.15
+/- 0.90
0.81
+/- 0.47
-29% n.s. 0.90
+/- 0.68
0.86
+/- 0.41
-4% n.s.
Gamma-amino butyrate
(75%/84% below dl)
0.053
+/- 0.008
0.053
+/- 0.08
0.053
+/- 0.007
-1% n.s. 0.053
+/-
0.006
0.051
+/- 0.004
-3% n.s.
Homocystine +
Homocysteine
(69%/86% below dl)
0.0055
+/- 0.0016
0.0087
+/-
0.0051
0.0057
+/- 0.0014
-34% 0.02 0.0078
+/-
0.0068
0.0054
+/- 0.0010
-30% n.s.
Hydroxy proline 2.19
+/- 0.80
2.34
+/- 0.90
1.92
+/- 0.58
-18% 0.03 2.54
+/- 0.63
2.15
+/- 0.51
-15% 0.04
Methionine Sulfoxide 0.315
+/- 0.21
0.371
+/- 0.22
0.335
+/- 0.16
-10% n.s. 0.341
+/- 0.15
0.432
+/- 0.30
+27% n.s.
Ornithine 6.0
+/- 1.7
5.0
+/- 1.2
6.5
+/- 1.9
+29% 0.008 6.3
+/- 1.8
6.00
+/- 1.4
-5% n.s.
Phospho ethanol amine 1.55
+/- 0.58
1.32
+/- 1.0
1.53
+/- 0.55
+16% n.s. 1.51
+/- 0.56
1.80
+/- 0.56
+19% n.s.
Phospho serine 0.024
+/- 0.044
0.055
+/- 1.0
0.015
+/- 0.007
-73% n.s. 0.058
+/- 0.08
0.017
+/- 0.009
-70% 0.05
Sarcosine 0.89
+/- 0.36
0.78
+/- 0.32
1.06
+/- 0.35
+35% 0.01 0.85
+/- 0.34
1.12
+/- 0.38
+32% 0.01
Taurine 16.8
+/- 5.8
13.7
+/- 6.1
17.7
+/- 5.7
+29% 0.07 15.5
+/- 5.8
19.9
+/- 5.9
+28% 0.03
Urea 309
+/- 87
329
+/- 105
270
+/- 62
-18% 0.04 257
+/- 71
252.
+/- 106
-2% n.s.
The average levels of secondary amino acids in plasma (in units of micromoles per 100 ml) measured in the Neurotypical group and the Autism Treatment and
Autism Placebo groups (pre and post) who completed the study are reported below, along with their standard deviations. The p-value for a t-test comparison of
the change in the level is reported. If the p-value is below 0.05, then the result is highlighted. In some cases data was below the detectable limit -if this was
greater than 20%, then we report the data as the % of the autism group and then the % of the neurotypical group below the detectable limit (dl).
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Page 20 of 30significantly greater improvement in Hyperactivity (p =
0.003), a marginally significant greater improvement in
Tantrumming (p = 0.009), and possibly significant greater
improvements in Receptive Language (p = 0.03), and
Overall (p = 0.02). There are possible trends (p < 0.10)
towards improvement in the areas of Expressive Lan-
guage (p = 0.06) and Play (p = 0.09)). The other areas of
the PGI-R yielded non-significant differences between
the treatment and the placebo group, but the treatment
group consistently scored higher in those other areas,
suggesting that larger studies may be needed to investi-
gate possible differences in those other areas.
Medication Effects
Since some participants were taking psychotropic medi-
cations, a comparison of the PGI-R scores was made
between the treatment group taking and not taking psy-
chotropic medications. There were no significant differ-
ences, but there was a trend that the group taking
psychotropic medications had less improvement than
those not taking medications for three subscales of the
PGI-R: expressive language (-46%, p = 0.08), play (-47%,
p = 0.09), sociability (-52%, p = 0.09).
Age Effects
The correlation of the Average Change of the PGI-R vs.
age was calculated for the treatment group, and found to
be r = - 0.20 (not significant). Figure 7 shows the Average
Change of the PGI-R vs. Age. Below age 20 there are
many Average Changes above 1, but after age 20 there
are no Average Changes above 1, but some are still posi-
tive. So, the greatest benefit appears to be for people
Table 10 Summary results for the four autism assessment tools, for the Arizona and National groups combined.
Placebo-Pre Placebo-Post Difference Supplement-
Pre
Supplement
Post
Difference P-Value
PGI-R (Average Change) +0.34
+/- 0.54
+0.67
+/- 0.65
0.008
ATEC (Total) 59
+/- 28
50
+/- 27
-9.6 63
+/- 22
51
+/- 20
-11.9 n.s.
SAS 5.2
+/- 2.6
5.2
+/- 2.6
0.0 5.4
+/- 2.0
5.1
+/- 2.2
-0.3 n.s.
PDD-BI
(Autism Composite)
-66
+/- 64
-79
+/- 68
-13.4 -62
+/- 51
-78
+/- 52
-16.4 n.s.
Note that the ATEC, SAS and PDD-BI are assessed at the beginning and end of the study, whereas the PGI-R is only assessed at the end, as it only evaluates the
changes observed. Only the PGI-R found a significant difference between the supplement and placebo groups, so it is highlighted in a bolder font.
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Figure 6 Results for the Parent Global Impressions - Revised, for the Arizona and National groups combined. The supplement group
had greater improvements in the PGI-R Average score (p = 0.008), and in the subscores for Receptive Language (p = 0.03), Hyperactivity (p =
0.003), Tantrumming (p = 0.009), and Overall (p = 0.02). The y-axis is from -3 (much worse) to 0 (no change) to +1 (slightly better) to +2 (better)
to +3 (much better).
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Page 21 of 30Table 11 Detailed results for the Parent Global Impressions-Revised, for the Arizona and National groups comibined.
Placebo Group
(n = 51)
Supplement Group
(n = 53)
Difference P-Value
Expr. Lang. 0.71
+/- 0.92
1.09
+/- 1.11
0.39 0.06
Rec. Lang. 0.51
+/- 0.81
0.91
+/- 1.01
0.40 0.03
Play 0.51
+/- 0.87
0.81
+/- 0.88
0.30 0.09
Cognition 0.43
+/- 0.84
0.74
+/- 1.04
0.31 n.s.
GI 0.35
+/- 1.09
0.68
+/- 1.11
0.33 n.s.
Sleep 0.13
+/- 0.99
0.30
+/- 0.87
0.17 n.s.
Sociability 0.63
+/- 0.92
0.77
+/- 1.00
0.15 n.s.
Hyperactivity -0.06
+/- 0.55
0.31
+/- 0.67
0.37 0.003
Tantrumming -0.10
+/- 0.80
0.40
+/- 1.08
0.51 0.009
Eye Contact 0.40
+/- 0.85
0.66
+/- 0.98
0.26 n.s.
Overall 0.56
+/- 0.86
1.02
+/- 1.00
0.46 0.02
Average
(of all the other scores)
0.34
+/- 0.54
0.67
+/- 0.65
0.32 0.008
Results with p-values below 0.05 are highlighted in a larger, bold font.
PGI-R:  Average Change vs. Age
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Figure 7 Average Change on the PGI-R vs. Age, for the Arizona and National Treatment group. There is a slight, non-significant
correlation of the Average Change vs. age, as indicated by the trendline. The y-axis is from -3 (much worse) to 0 (no change) to +1 (slightly
better) to +2 (better) to +3 (much better).
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Page 22 of 30under the age of 20, but there were some reported
improvements for people up to the highest age in the
study (mid-forties).
Figure 7 also provides a visual of the large variation in
response; some participants reported little or no
improvement, some reported moderate improvement (1
= slightly better), and some reported substantial
improvement (2 = better, 3 = much better).
There were only 3 female participants in the supple-
ment group, which is too few to make any generaliza-
t i o n-t h e i rA v e r a g eC h a n g es c o r e sw e r e0 . 2 ,0 . 5 ,a n d
0.8, similar to those of the males.
Correlation with Biomarkers
The correlation of the Average Change of the PGI-R vs.
initial (baseline) biomarkers of nutritional status were
calculated for the supplement group of the Arizona
study (biomarkers were only measured for the Arizona
group). The biomarkers with correlations larger in mag-
nitude than 0.46 (corresponding to p < 0.05) are listed
in Table 12. However, since multiple comparisons were
made, none of these correlations were significant after
making a Bonferroni correction, so these correlations
are at most possibly significant. Vitamin K had the
strongest correlation with the Average Change of the
PGI-R, followed by biotin and lipoic acid.
Regression Analysis
Since three biomarkers had possibly significant correla-
tions with the Average Change of the PGI-R, a regres-
sion analysis was conducted to determine which set of
biomarkers were the best predictors of improvement,
and hence determine which children were most likely to
benefit from the vitamin/mineral supplement. The
results are displayed in Table 13. A very strong and
highly significant association of the biomarkers with the
Average Change of the PGI-R was found (adjusted R2 =
0.61, p < 0.0005), with the most significant biomarkers
being vitamin K (p = 0.03) and Biotin (p = 0.04).
Discussion
Discussion of Nutritional/Metabolic Changes
In general, although we focus on averages in the follow-
ing sections, it is important to realize the breadth of the
distributions. So, although children with autism may
(for example) have average levels of vitamin B1, there is
a subset with lower levels, so increases in the average
level of vitamin B1 may be more beneficial to those with
lower levels. Similarly, although children with autism
tend to have lower levels of (for example) glutathione,
some children have normal levels, but many have low
levels; improvements in the average level are probably
most beneficial to those with lower levels.
Also, it is important to point out that “average” levels
of the neurotypical group may not necessarily be opti-
mal, as they were on typical western diets that are prob-
ably not nutritionally optimal.
Vitamins
Overall, the supplement increased the level of most vita-
mins, including vitamins B1, B3, B5, B6, folic acid, B12,
C, E, and biotin. It appears that higher levels of vitamin
B2 are needed in the supplement to affect blood levels.
Carotene levels improved, but were still somewhat low,
so higher amounts are needed. It is interesting that sup-
plementation with carotenes and modest amounts of
vitamin A did not significantly alter vitamin A levels,
which remained normal; this is consistent with the body
only converting carotenes to vitamin A if vitamin A
levels are low.
The supplement also improved two functional biomar-
kers in urine, FIGLU and methylmalonic acid, indicating
the supplement decreased the need for folic acid and
vitamin B12, respectively. Levels of FIGLU and methyl-
malonic actually decreased somewhat below the levels of
the neurotypical controls; this may be a good result, as
some typical children do not have optimal nutritional
intake. SAM levels normalized, and uridine levels
improved but did not normalize, suggesting that more
vitamin B12 and/or folinic might be needed.
Vitamin C levels in the autism group were initially
somewhat above that of the neurotypical group, and the
supplement raised those levels significantly. This is
probably beneficial, as the children with autism initially
had high oxidative stress, and the supplement signifi-
cantly decreased the level of oxidative stress, probably in
part due to the vitamin C in the supplement.
Vitamin D decreased in both the treatment and pla-
cebo group - this was apparently a seasonal effect, as
Table 12 Correlation of PGI-R Average Score with
Biomarkers, for the Arizona Treatment group only.
Biomarker Correlation Coefficient (r) p-value
Vitamin K - 0.74 p < 0.01
Biotin - 0.67 p < 0.01
Lipoic Acid + 0.52 p < 0.05
Correlations of 0.46 or larger in magnitude are reported, corresponding to a
p-value of 0.05, in order starting with the strongest correlations.
Table 13 Result of Regression Analysis of PGI-R Average
Score with Biomarkers, for the Arizona Treatment Group
only
PGI-R
Significant Biomarkers
Adjusted R
2 0.61
P-value 0.0005
Primary variables Vit K (p = 0.03)
Biotin (p = 0.04)
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fall/winter, and most vitamin D in the body is produced
by sunlight. It appears that much higher levels of vita-
min D are needed to affect blood levels of vitamin D.
Minerals
Caution needs to be used in interpreting the results for
minerals, as absolute levels are not necessarily the best
w a yt om e a s u r eb o d ys t o r e sa n dt h en e e df o rm i n e r a l s .
Also, there is some debate over which compartment
(WB, RBC, serum, urine, etc) is the best to use in mea-
suring a given mineral. For a full discussion of these
complex issues, see Gibson 2005 [32].
Overall, the supplement tended to increase the levels
of many essential minerals, including calcium, iodine,
lithium, manganese, molybdenum, and selenium. The
increase in lithium levels was large (this form of lithium
w a sv e r yw e l la b s o r b e d ) ,s ol e s sl i t h i u mm a yb en e e d e d
in future studies. Magnesium levels in whole blood sig-
nificantly increased and normalized, but there was a
possible decrease in RBC levels, and no change in serum
levels, which is somewhat inconsistent; however, overall,
it seems that the increase in whole blood levels was the
most significant/important.
The supplement also normalized RBC iron, from
slightly (but significantly) higher initial levels compared
to the neurotypical average, to levels close to that of the
neurotypical group. RBC iron is a measure of the total
iron in the RBC, and about 65% of the body’si r o ni si n
the RBC [33], so RBC iron may be a reasonable indica-
tor of total body stores of iron. The importance of ele-
vations in RBC iron (statistically significant), serum
ferritin and serum iron (non-significant) are unclear;
supplementation resulted in all three declining to the
neurotypical average level. Increases in serum ferritin
and altered iron metabolism are known to occur with
inflammation. This may also hold for increased oxidative
stress. In the baseline evaluations the regression analysis
found that RBC iron was significantly associated with all
three assessments of autism severity (p < 0.01) [20].
Based on these findings, further evaluation of iron meta-
bolism in autism is warranted.
Levels of copper, and zinc were not significantly
affected (note that copper is not included in the supple-
ment since children with autism seem to generally have
adequate or slightly high levels of it). It should be
pointed out that zinc levels began and ended in the nor-
mal range. It is possible that increased zinc supplemen-
tation would normalize the slightly elevated copper
levels. Chromium decreased to a normal level, but the
change was not significant.
Regarding the placebo group, there was a significant
increase in manganese, but other changes appeared to
be small fluctuations around the average level in neuro-
typical children.
Sulfation
The supplement substantially improved sulfate status,
but sulfate levels were still low, suggesting that higher
levels of MSM or other sources of sulfate such as
Epsom salt (magnesium sulfate) baths are needed. Sulfur
is the third most common mineral in the body [34].
Most sulfate is produced in vivo by metabolism of
cysteine [35]. Sulfation is important for many reactions
including detoxification, inactivation of catecholamines,
synthesis of brain tissue, sulfation of mucin proteins
which line the gastrointestinal tract, and more. The
measurement of total plasma sulfate involves many sub-
stances in the plasma, including neurotransmitters, ster-
oids, glycosaminoglycans, phenols, amino acids,
peptides, and other molecules. Low free and total
plasma sulfate in children with autism has been pre-
viously reported in two studies [36,37], and is consistent
with four studies [36,38-40] which found that children
with ASD had a significantly decreased sulfation capa-
city compared to controls, based on decreased ability to
detoxify paracetamol (acetaminophen). The finding of
low plasma sulfate is also consistent with a large study
that found high sulfate in the urine of children with aut-
ism [41], as sulfate wasting in the urine partly explains
low levels in the plasma. ATP is required for the kidneys
to resorb sulfate, and the accompanying study [20]
found that ATP was moderately correlated with levels of
free and total plasma sulfate (r = 0.32 and 0.44, respec-
tively), so this suggests that low levels of ATP are a con-
tributor to decreased sulfate in children with autism.
One study [41] also reported high levels of urinary sul-
fite in children with autism, suggesting that there was a
problem of converting sulfite to sulfate in the mitochon-
dria. In 38% of cases (14/38) urinary sulfite and sulfate
levels improved by giving 50 mcg of molybdenum, pre-
s u m a b l ys i n c et h ee n z y m ef o rc o n v e r t i n gs u l f i t et os u l -
fate (sulfite oxidase) contains molybdenum. The
vitamin/mineral supplement in this study contained
molybdenum (150 mcg for a 30 kg child), so this may
also have contributed to increases in sulfate levels.
Methylation, Glutathione and Oxidative Stress
Methylation improved to near-normal levels, as indi-
cated by improvements in SAM and uridine. SAM is the
primary methyl donor for methylation of DNA, RNA,
proteins, phospholipids, and neurotransmitters. The
improvement in SAM may in part be due to improve-
ments in ATP, since that is the co-factor needed to con-
vert methionine to SAM. The methylation pathway is
diagrammed in Figure 8.
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tathione (an important anti-oxidant and defense against
toxic metals). The supplement substantially reduced oxi-
dative stress to near-normal levels, as evidenced by
improved ratio of GSSG:GSH and improved levels of
nitrotyrosine. NADPH is the co-factor needed to recycle
GSSG to GSH (see Figure 9), so normalizing the level of
NADPH probably was the major factor in improving the
GSSG:GSH ratio.
Previous studies [9,10] have demonstrated that oral
folinic acid, oral trimethylglycine, and subcutaneous
injections of methyl Vitamin B12 were able to greatly
improve methylation, glutathione, and oxidative stress,
similar to the results here. This suggests that the oral
supplement used in this study may be a reasonable
alternative to subcutaneous injections of methyl-B12.
Oral intake of vitamin B12 has a complex absorption
mechanism involving “intrinsic factor”,a n dt y p i c a l l y
only 1% of oral vitamin B12 is absorbed, so it is interest-
ing that the levels used in this study were sufficient to
substantially improve methylation, glutathione, and oxi-
dative stress. The vitamin C in the present supplement
probably also helped reduce oxidative stress.
The current observed improvements in methylation
and GSH are similar to effects of treatment with NADH
[42] and ribose [42], but neither ribose nor NADH had
significant effect on improving levels of GSSG after two
weeks.
ATP, NADH, NADPH, CoQ10
ATP, NADH, NADPH, and CoQ10 are important co-fac-
tors for many metabolic processes in the body. ATP is a
p r i m a r ye n e r g ys o u r c ef o rt h eb o d ya n dt h eb r a i n .T h e
CoQ10 in the supplement was very well absorbed, so that
the relatively modest dosage resulted in a large, significant
increase in CoQ10 levels. The supplement significantly
increased the plasma levels of ATP, NADH, and NADPH,
from about 25% below normal to normal levels. Plasma
ATP may be a biomarker of general ATP status in the
body, and may be related to overall level of ATP, and/or
the ability to recycle ATP, and/or the ability to transport
ATP where needed - more research is needed to interpret
the importance of plasma ATP. Many children with aut-
ism have low muscle tone and impaired endurance, and it
is interesting to hypothesize if those symptoms relate to
decreased ATP levels, and if improvements in plasma
A T Pw i l lr e s u l ti ni m p r o v e m e n t si nm u s c l et o n ea n d
endurance - those symptoms were not assessed in this
study, but would be interesting to assess in future.
The results of vitamin/mineral supplementation on
ATP, NADH, NADPH is similar to the results of supple-
mentation with NADH [42] and ribose [42], since NADH
is easily converted to NADPH, which is a co-factor for
making ribose, which is a building block of ATP, NADH,
NADPH, and many other important substances.
Primary and Secondary Amino Acids
There were no significant or marginally significant
changes. Most small changes in primary and secondary
essential amino acids appeared to involve modest fluc-
tuations around the average level of the neurotypicals.
One possible exception is the slight decrease in serine
coupled due to increase in glycine. Serine is converted
to glycine in an enzymatic reaction requiring tetrahydro-
folate as a co-factor - this may suggest a small increase
in production of tetrahydrofolate.
Figure 8 Conversion of Methionine to SAM to SAH to Homocysteine. Homocysteine is then either recycled to methionine or converted into
cystathionine.
Figure 9 R e d u c t i o no fG S S Gt oG S H( n e tr e s u l to fam o r e
complex process which involves FADH).
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A previous paper [20] reports on a comparison of the
nutritional and metabolic status of the participants tak-
ing medications vs. those not taking medications. The
only differences with a p-value less then 0.01 were lower
RBC copper (-9% lower, p = 0.001) and higher plasma
methionine sulfoxide (+35% higher, p = 0.002) for the
autism medication group compared to the autism no-
medication group. The sample size in this paper is too
small to determine if medications had an effect on
changes in the nutritional and metabolic status of the
treatment group, but since no changes in medication
were made during the study, this was probably a minor
effect at most.
Discussion of Placebo
The placebo group had a few significant changes, includ-
ing significant increases in biotin, CoQ10, WB manga-
nese, and SAM. In all four cases the supplement group
had similar changes (biotin, WB manganese) or larger
changes (CoQ10, SAM). Some of these findings might be
due to laboratory error (drift in standards), but that
seems unlikely. Some of the changes may be due to ran-
dom fluctuations in diet, or possibly due to seasonal
effects (i.e., baseline values were measured in summer/
fall (June-October) and final values in fall/winter (Sep-
tember to January). Finally, it may be that the natural
plant-based flavorings used in the placebo (not in the
supplement) contained modest amounts of biotin and
other nutrients.
Discussion of Effect on Symptoms
The supplement group had significantly greater improve-
ment that the placebo group on the Average Change of
the PGI-R. The supplement group had greater improve-
ment than the placebo group on all of the subscales, with
several of the results being significant (p < 0.005), mar-
ginally significant (p < 0.01), or possibly significant (p <
0.05). Although the magnitude of the effects were mod-
est, the supplement group reported roughly twice the
improvement as did the placebo group on the Average
Change score (the average of all the PGI-R scores). Since
the supplement resulted in many significant improve-
ments in nutritional and metabolic status after three
months, we hypothesize be that the child’so v e r a l lh e a l t h
and learning ability is improved at that point, but that
more time may be needed for the increase in learning
ability to fully translate into greater skills in language,
social understanding, and behavior.
For the other three assessment tools, the supplement
group also had a slightly greater improvement than did
the placebo group, but the effect was not significant. This
suggests that the PGI-R is more sensitive at detecting
changes, which is what it was designed for, whereas the
other scales measure overall autism severity. It should be
n o t e dt h a tt h eP G I - Ru s e sa7 - p o i n ts c a l e ,w h e r e a st h e
ATEC and PDD-BI use a 3 to 4 point scale, and that may
be part of the reason why the PGI-R appears to be more
sensitive. More importantly, the PGI-R directly assesses
the degree of improvement, whereas the other assess-
ment tools only indirectly assess the degree of improve-
ment by calculating a small difference between two large
numbers (initial and final), which leads to a greater
uncertainty in the degree of improvement.
Correlation with Biomarkers
The correlation of three biomarkers with the Average
Change of the PGI-R is interesting. The correlations need
to be interpreted cautiously, because the sample size
( o n l yt h eA r i z o n at r e a t m e n tgroup) is small. The autism
group had lower levels of biotin than did the neurotypical
g r o u p( - 2 0 % ,p=0 . 0 0 1 )a tt h es t a r to ft h es t u d y ,a n dt h e
supplement significantly increased levels of biotin (+51%,
p = 0.008) in the treatment group. So, it makes sense that
children with low levels of biotin would be more likely to
benefit from supplementation. Biotin is an important co-
factor for four carboxylases that regulate gluconeogenesis
(generation of glucose from non-carbohydrate sources),
fatty acid synthesis, and the Krebs cycle.
The autism group initially had levels of vitamin K that
were similar to the control group. Vitamin K was the
only vitamin not included in the supplement, and the
level did not significantly change (+15%, n.s.) during the
study. The primary role of vitamin K is in blood coagula-
tion, which is not reported as a common problem in aut-
ism, which is why it was not included in the supplement
in this study. However, a previous study [20] found by
regression analysis that levels of vitamin K were some-
what associated with variation in the severity of autism.
So, the correlation of vitamin K with degree of improve-
ment is puzzling.
What biotin and vitamin K have in common is that
both are made in substantial amounts by beneficial
intestinal bacteria. It is estimated that approximately half
of the biotin and half of the vitamin K in humans comes
from their intestinal bacteria [43]. One of the common
causes of biotin or vitamin K deficiency is antibiotic
usage, because some antibiotics destroy the beneficial
bacteria that produce them [43]. Several studies have
reported that one major difference in the medical history
of children with autism compared to neurotypical chil-
dren is a much higher usage of oral antibiotics antibiotic
[44-47]. So, it could be that excessive oral antibiotic
usage contributed to lower levels of biotin and vitamin K
in some children. Vitamin K occurs in two natural forms,
vitamin K1 (phylloquinone) produced by plants, and vita-
min K2 (menaquinone) produced by intestinal bacteria.
In this study we measured total vitamin K (K1 plus K2);
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forms individually.
We analyzed the possible correlation of levels of vita-
min K and biotin in the autism group at the start of the
study, and found that they were significantly correlated
(r = 0.44, p < 0.001). This is consistent with both being
partially produced by beneficial intestinal bacteria. One
study found a very high correlation of GI problems with
autism severity (r = 0.59, p < 0.001) [48]. So, it appears
that the correlation of improvement in autism symp-
toms with biotin and vitamin K may relate to a lack of
beneficial bacteria which produce biotin and vitamin K,
so that supplementation with biotin was beneficial. This
suggests that supplementation with vitamin K would be
beneficial, especially for those with low levels of vitamin
K (the standard deviation of vitamin K levels in the aut-
ism group was large).
The negative correlation of lipoic acid with the Aver-
age Change of the PGI-R is interesting. The supplement
did not contain lipoic acid, and it did not affect levels of
lipoic acid, so it appears that children were more likely
to improve if they already had sufficient lipoic acid,
whereas a lower level of lipoic acid seemed to be asso-
ciated with less improvement. However, this correlation
is not as strong as that for biotin and vitamin K. More
research into supplementation with lipoic acid may be
warranted.
Regression Analysis
The regression analysis found that the Average Change
o ft h eP G I - Rw a sv e r ys t r o n g l ya s s o c i a t e dw i t hs e v e r a l
biomarkers, with vitamin K and biotin being the most
significant. This suggests that children with low biotin
or low vitamin K were most likely to benefit from the
multi-vitamin/mineral supplement, for reasons discussed
in the preceeding section. This suggests that vitamin K
should be added to future formulations.
It is important to realize that vitamin levels are not
independent variables, but are usually significantly cor-
related with one another, because they often occur in
the same foods. So, in interpreting these results, it may
be that biotin and vitamin K are also markers of overall
nutritional status, and their individual importance may
be less important.
General Discussion
At the start of the study the children with autism had
many statistically significant differences (p < 0.001) in
their nutritional and metabolic status compared to the
neurotypical group [20], including: Low levels of biotin,
glutathione, SAM, plasma ATP, NADH, NADPH,
plasma sulfate (free and total), and plasma tryptophan;
also high levels of oxidative stress biomarkers and evi-
dence of impaired methylation (high uridine). By the
end of the treatment study, these biomarkers had all
improved or even normalized. Also, the baseline study
[20] found that levels of several vitamins, minerals, and
amino acids were strongly associated with variation in
autism severity. Vitamins and minerals act as enzymatic
co-factors for hundreds of important enzymatic reac-
tions in the body, so low levels of them can result in
impaired metabolic functioning. Also, many genetic var-
iations result in impaired enzymatic activity, resulting in
an increased need for vitamin/mineral co-factors for
normal metabolic functioning. This study was only able
to assess a limited portion of human metabolism, and it
is likely that other metabolic problems exist in children
with autism and possible that the vitamin/mineral sup-
plement could improve other problems as well as those
reported here. For example, vitamins and minerals
are required co-factors for the production of many
neurotransmitters and their pre-cursors, so vitamin/
mineral supplementation may have also affected neuro-
transmitter status, and that may have contributed to
improvements in autism severity and overall symptoms.
So, it is not surprising that nutritional supplementation
would improve metabolic functioning in some children
with autism, and it is very interesting that nutritional
supplementation also resulted in significant improve-
ments in the Average Score of the PGI-R, as well
as improvements in several of its subscores. Some chil-
dren improved much more than others, presumably
because some had a greater need for nutritional
supplementation.
This study is consistent with several other studies that
reported that vitamin/mineral supplementation is benefi-
cial in treating children with autism. A 30-week, double-
blind, placebo-controlled study [12] of high-dose vitamin
C (110 mg/ kg) found a reduction in autism severity. One
open-label study [49] found that micronutrient supple-
mentation was comparable or more effective than treat-
ment with pharmaceuticals in terms of improvements in
the Childhood Autism Rating Scale, Childhood Psychia-
tric Rating Scale, Clinical Global Impressions, and Self-
Injurious Behavior. A small randomized, double-blind,
placebo-controlled study of a moderate-dose vitamin/
mineral supplement was found to be beneficial to chil-
dren with autism, primarily in the areas of sleep and gas-
trointestinal symptoms [14]. There have been many
studies of high dose vitamin B6 therapy in children with
autism [13], with most showing beneficial effects; those
studies investigated very high dosages, generally 500-
1000 mg, compared to the current study which investi-
gated a lower dosage (40 mg for a 30 kg child) which is
still substantially higher than the RDA (0.6 mg), and was
sufficient to substantially increase P5P levels inside RBC
(+187%, p < 0.001). Some children and adults may benefit
from adding high-dosage vitamin B6 to a broad-spectrum
vitamin/mineral supplement such as investigated in this
study.
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vitamin/mineral supplement requires only a few minutes a
day, is relatively inexpensive, and is very safe. Although it
will not help all children and adults with autism, it appears
that a significant percentage are likely to improve to some
degree after only three months, and longer-term use is
likely very safe and may result in even greater benefits.
Also, the vitamin/mineral supplement improved many
nutritional and metabolic problems. So, vitamin/mineral
therapy seems to be a reasonable adjunct therapy for help-
ing some children and adults with autism, and can be
easily used in conjunction with other therapies (behavior
therapy, speech therapy, etc.).
Limitations of this study
1) The diagnosis of an autism spectrum disorder by a qua-
lified medical professional was verified in writing, but
there no additional verification. Similarly, for the neuroty-
pical children, no additional verification was made beyond
the parental report. The supplement group included a
somewhat higher fraction of individuals with classic aut-
ism than did the placebo group, since random assignment
was done and severity of diagnosis was not controlled for.
However, the effect on the results is probably small, since
the analysis investigated the change in symptoms, not the
final symptoms only.
2 )T h es a m p l es i z ew a sl a r g ee n o u g ht oo b s e r v em a n y
major significant differences between the two groups; but
a larger sample size is needed for appropriate statistical
power for more subtle, possibly significant differences.
3) The formulation of the supplement was very good;
the present data suggests ways to further improve compo-
sition and dosage optimization and titration.
4) Seasonal changes slightly affected some results (vita-
min D) and possibly others.
5) The placebo contained small amounts of natural
plant-based extracts that may have slightly affected
some results.
6) Some of the children (45%) were taking various types
of medications, which did not change during the study. A
comparison of the baseline levels of the autism groups tak-
ing and not-taking medications revealed little difference
between the two groups in their nutritional and metabolic
status [20]. There was a trend that the medicated group
had less improvement than the unmedicated group in the
Average Score of the PGI-R.
7) The length of the study (three months) may not have
been long enough to observe the full-effect of the supple-
ment, and longer treatment may result in larger effect.
Conclusions
The vitamin/mineral supplement was found to be gener-
ally well-absorbed and metabolically active, resulting in
improvements in biotin, glutathione, methylation,
oxidative stress, ATP, NADPH, NADPH, and sulfate.
The supplement was well-tolerated, with few side-
effects, although for a few participants their individually
titrated dose was lower than originally prescribed.
The supplement group improved significantly more
than the placebo group on the PGI-R Average Change
and on several of the PGI-R subscales. On the PGI-R
subscales, the most significant improvements were (in
order) in the areas of Hyperactivity, Tantrumming,
Overall, and Receptive Language. We hypothesize that
longer treatment may result in greater improvements.
There was wide variation in degree of improvement,
with some participants experiencing little benefit, and
some experiencing moderate or substantial benefit.
T h ed a t af r o mt h i ss t u d ys t r o n g l ys u g g e s t st h a to r a l
vitamin/mineral supplementation is beneficial in
improving the nutritional and metabolic status of chil-
dren with autism, and in reducing their symptoms.
Based on the present findings, vitamin/mineral supple-
mentation should be considered as an adjunct therapy
for most children and adults with autism, especially
when any of the metabolic problems discussed in this
paper are documented as present.
The data from this study serves as a useful guide for
future formulations of vitamin/mineral supplements for
children with autism. Additional sources of sulfate, such
as MSM or Epsom salt baths, may be needed to normal-
ize sulfate levels.
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